What is the 13F Pro Quality Score for IKT?

13F Pro ranks Inhibikase Therapeutics, Inc. (IKT) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IKT's current score at https://13fpro.ai/research/IKT (free sign-up required for the full ranking).

Where does 13F Pro source IKT data?

All Inhibikase Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Inhibikase Therapeutics, Inc. files with the SEC under CIK 1750149. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IKT in?

Inhibikase Therapeutics, Inc. (IKT) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IKT research updated on 13F Pro?

IKT's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Inhibikase Therapeutics, Inc.(IKT)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1750149 IKT stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $3.1M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

IKT Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Inhibikase Therapeutics, Inc. (IKT), a Healthcare sector company. IKT is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $3.1m in revenue. Based on the latest XBRL financial filings (Q1 2026), Inhibikase Therapeutics, Inc. reports net income of $-16.4M, free cash flow of $-12.1M. Top institutional holders of IKT by reported 13-F value include Sands Capital Ventures,, Soleus Capital Management, L.P., Fairmount Funds Management, based on the most recent SEC filings. IKT trades on the Nasdaq exchange and files with the SEC under CIK 1750149. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IKT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Inhibikase Therapeutics, Inc. directly from SEC EDGAR.

Revenue

Q1 2026

$0.00

Net Income

Q1 2026

$-16.4M

Free Cash Flow

Q1 2026

$-12.1M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2024

FY21 $3.1MFY22 $123.4KFY23 $260.5KFY24 $0.00

Net Income

-44.6% YoY

$-27.5MFY 2024

FY21 $-14.8MFY22 $-18.1MFY23 $-19.0MFY24 $-27.5M

Operating Income

-42.3% YoY

$-28.6MFY 2024

FY21 $-14.8MFY22 $-18.1MFY23 $-20.1MFY24 $-28.6M

EPS (Diluted)

+63.3% YoY

$-1.16FY 2024

FY21 $-0.81FY22 $-4.28FY23 $-3.16FY24 $-1.16

Total Assets

+579.7% YoY

$98.6MFY 2024

FY21 $42.5MFY22 $24.9MFY23 $14.5MFY24 $98.6M

Total Debt

-79.2% YoY

$110.5KFY 2024

FY21 $248.9KFY22 $145.8KFY23 $531.9KFY24 $110.5K

Op. Cash Flow

-5.9% YoY

$-19.1MFY 2024

FY21 $-14.3MFY22 $-17.4MFY23 $-18.1MFY24 $-19.1M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$0.00 -100.0%	$260.5K +111.0%	$123.4K -96.0%	$3.1M +343.9%	$698.5K
Net Income	$-27.5M -44.6%	$-19.0M -5.4%	$-18.1M -22.1%	$-14.8M -419.2%	$-2.8M
Operating Income	$-28.6M -42.3%	$-20.1M -10.8%	$-18.1M -22.8%	$-14.8M -423.9%	$-2.8M
EPS (Diluted)	$-1.16 +63.3%	$-3.16 +26.2%	$-4.28 -428.4%	$-0.81	—
Total Assets	$98.6M +579.7%	$14.5M -41.8%	$24.9M -41.3%	$42.5M +187.3%	$14.8M
Total Debt	$110.5K -79.2%	$531.9K +264.7%	$145.8K -41.4%	$248.9K	—
Operating Cash Flow	$-19.1M -5.9%	$-18.1M -4.2%	$-17.4M -21.4%	$-14.3M -1165.9%	$-1.1M

AI Insight: IKT Financial Trends

Pre-revenue biotech burning cash at accelerating rate; equity raised in Q4 2025 provides runway but losses widening.

• Operating losses expanded from $5M in Q2 2024 to $18M in Q1 2026, a 3.6x increase over 22 months.

• Operating cash burn worsened from $4M–$6M per quarter to $8M–$12M in latest two quarters.

• Equity base jumped to $173M in Q4 2025 (likely financing), then declined to $168M by Q1 2026.

⚠ No revenue across all eight quarters; cash burn trajectory unsustainable without near-term clinical milestone or asset sale.

⚠ Q1 2026 operating loss of $18M highest on record; monthly burn rate ~$6M suggests 28-month runway at current pace.

AI Insight: IKT Ratio Trends

Inhibikase remains deeply unprofitable with negative ROIC averaging -50% over trailing twelve months; modest Q4 2025 improvement reversed in Q1 2026.

• ROE improved from -65.5% (Q3 2025) to -29.5% (Q4 2025), then deteriorated to -39.1% (Q1 2026).

• ROIC tracked ROE declines throughout 2025, ranging -31.9% to -70.1%, with TTM ROIC at -32.9%.

• Debt-to-equity maintained at 0.00 through Q1 2026, indicating minimal leverage but also no debt financing.

⚠ Q1 2026 ROE/ROIC deterioration (-39.1%/-42.6%) reverses Q4 2025 recovery; trend direction unclear.

⚠ No margin or cash-flow data available; cannot assess profitability path or operational leverage improvement.

Get alerted when IKT's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Inhibikase Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of IKT

Sands Capital Ventures, LLC
$21.9M13,018,965 sh
Soleus Capital Management, L.P.
$18.3M10,875,000 sh
Fairmount Funds Management LLC
$14.5M8,625,000 sh
Trails Edge Capital Partners, LP
$13.5M8,057,345 sh
ADAR1 Capital Management, LLC
$11.1M6,606,572 sh
BlackRock, Inc.
$10.6M6,303,433 sh
Blackstone Inc.
$10.0M5,938,276 sh
Siren, L.L.C.
$9.8M5,850,000 sh
Commodore Capital LP
$9.1M5,397,488 sh
VANGUARD CAPITAL MANAGEMENT LLC
$7.5M4,450,665 sh

Fund	Value	Shares
Sands Capital Ventures, LLC	$21.9M	13,018,965
Soleus Capital Management, L.P.	$18.3M	10,875,000
Fairmount Funds Management LLC	$14.5M	8,625,000
Trails Edge Capital Partners, LP	$13.5M	8,057,345
ADAR1 Capital Management, LLC	$11.1M	6,606,572
BlackRock, Inc.	$10.6M	6,303,433
Blackstone Inc.	$10.0M	5,938,276
Siren, L.L.C.	$9.8M	5,850,000
Commodore Capital LP	$9.1M	5,397,488
VANGUARD CAPITAL MANAGEMENT LLC	$7.5M	4,450,665

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IKT on your watchlist

Track score changes the day Inhibikase Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IKT a good stock to buy?

13F Pro's AI-powered analysis of Inhibikase Therapeutics, Inc. (IKT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IKT are available on the IKT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IKT?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IKT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Inhibikase Therapeutics, Inc.'s investment landscape.